Anti-proliferative effect of pentacyclic triterpenes associated with glycogen accumulation in A549 cells

Chinese Journal of New Drugs

Volumn 20, Issue 23, 2011, Pages 2350-2353

  Liu, Jun ^a   Wang, Xue ^a   Luo, Dan ^a   Sun, Hong Bin ^a   Shang, Jing ^a   Zhang, Lu Yong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

A549 cell; Glycogen metabolism; Glycogen phosphorylase; Pentacyclic triterpenes

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GLYCOGEN PHOSPHORYLASE; MASLINIC ACID; OLEANOLIC ACID; TRITERPENE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG EFFICACY; GLYCOGEN ANALYSIS; GLYCOGEN METABOLISM; IC 50; LUNG NON SMALL CELL CANCER; TREATMENT OUTCOME;

EID: 84859502506     PISSN: 10033734     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. MATHUPALA S P, REMPEL A, PEDERSEN P L. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexoinase[J]. J Bioenerg Biomembr, 1997, 29(4): 339-343.
2. NEWGARD C B, HWANG P K, FLETTERICK R J. The family of glycogen phosphorylase: structure and function[J]. Crit Rev Biochem Mol Biol, 1989, 24(1): 69-99.
3. SHIMADA S, MAENO M, AKAGI M, et al. Immunohistochemical detection of glycogen phosphorylase isoenzymes in rat and human tissues[J]. Histochem J, 1986, 18(6): 334-338.
4. DZUBAK P, HAJDUCH M, VYDRA D, et al. Pharmacological activities of natural triterpenoids and their therapeutic implications[J]. Nat Prod Rep, 2006, 23(3): 394-411.
5. CHEN J, LIU J, ZHANG L Y. Pentacyclic triterpenes. Part 3: Synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase[J]. Bioorg Med Chem Lett, 2006, 16(11): 2915-2919.
6. WEN X, ZHANG P H, LIU J, et al. Pentacyclic triterpenes. Part 2: Synthesis and biological evaluation of maslinic acid derivatives as glycogen phosphorylase inhibitors[J]. Bioorg Med Chem Lett, 2006, 16(3): 722-726.
7. WEN X, SUN H B, LIU J, et al. Pentacyclic triterpenes. Part 1: the first examples of naturally occurring pentacyclic triterpenes as a new class of inhibitors of glycogen phosphorylases[J]. Bioorg Med Chem Lett, 2005, 15(22): 4944-4948.
8. CHEN J, LIU J, GONG Y C, et al. Synthesis and biological evaluation of ursolic acid derivatives as novel inhibitors of glycogen phosphorylase[J]. China Pharm Lett, 2006, 37(5): 397-401.
9. MOLLER D E. New drug targets for type2 diabetes and themetabolicsyndrome[J]. Nature, 2001, 414(6865): 821-827.
10. OIKONOMAKOS N G. Glycogen phosphorylase as a molecar target for type2 diabetes therapy[J]. Curr Protein Pept Sci, 2002, 3(6): 561-586.
11. TRACEY W R, TREADWAY J L, MAGEE W P, et al. Cardioprotective effects of ingliforib, a novel glycogen phospholase inhibitor[J]. Am J Physiol Heart Cric Physiol, 2004, 286(3): H1177-H1184.
12. SCHNIER J B, NISHI K, MONKS A, et al. Inhibition of glycogen phosphorylase (GP) by CP-91, 149 induces growth inhibition correlating with brain GP expression[J]. Biochem Biophys Res Commun, 2003, 309(1): 126-134.
13. JOHNSON L N. Glycogen phosphorylase: control by phosphorylation and allosteric effectors[J]. FASEB J, 1992, 6(6): 2274-2282.
14. PEDERSEN B A, CHENG C, WILSON W A, et al. Regulation of glycogen synthase. Identification of residues involved in regulation by the allosteric ligand glucose-6-p and by phosphorylation[J]. J Biol Chem, 2000, 275(36): 27753-27761.
15. SHIMADA S, TASHIMA S, YAMAGUSHI K, et al. Carcinogenesis of intestinal-type gastric cancer and colorectal cancer is commonly accompanied by expression of brain (fetal)-type glycogen phosphorylase[J]. Exp Clin Cancer Res, 1999, 18(1): 111-118.
16. WILSON K S, ROBERTS H, LEEK R, et al. Differential gene expression patterns in HER2/neu-positive and negative breast cancer lines and tissues[J]. Am J Pathol, 2002, 161(4): 1171-1185.
17. HENG M C, SONG M K, HARKER J, et al. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters[J]. Br J Dermatol, 2000, 143(5): 937-949.